Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.47 |
| ▸ | KDR | P35968 | 11/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIF5B | P33176 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491001 | 0.81 | GPR119 (0.44) | — | |
| SCHEMBL4494330 | 0.80 | MEN1 (0.44) | EGFRKDR | |
| SCHEMBL3055764 | 0.77 | KDR (0.52) | EGFRKDRRETKIF5BCLK1 | |
| SCHEMBL3929974 | 0.77 | EGFR (0.33) | EGFRKDR | |
| SCHEMBL5239750 | 0.74 | KDR (0.60) | EGFRKDRRETKIF5BDYRK1A | |
| SCHEMBL4275254 | 0.74 | KDR (0.49) | EGFRKDRRETKIF5BCLK1 | |
| SCHEMBL5235212 | 0.73 | KDR (0.59) | EGFRKDRRETKIF5BDYRK1A | |
| SCHEMBL689999 | 0.70 | EGFR (0.46) | EGFRKDRRETKIF5BCLK1 | |
| SCHEMBL4491809 | 0.69 | EGFR (0.32) | EGFRKDR | |
| SCHEMBL2059480 | 0.69 | SMN1; SMN2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | EGFR 3991/4885KDR 3055/4885RET 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.